Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange in Severe Drug Induced Liver Injury
NCT04015570Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Randomised, open-label trial in drug induced liver injury (DILI) and chronic liver disease (CLD) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Transplant free survival at Day 28. Status: unknown.
02
Conditions
drug induced liver injury (DILI)chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT04015570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015570.